Development and Optimization of an ELISA to Quantitate C3(H2O) as a Marker of Human Disease

Frontiers in Immunology - Switzerland
doi 10.3389/fimmu.2019.00703
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

Evaluation of the ELISA-F29 Test as an Early Marker of Therapeutic Efficacy in Adults With Chronic Chagas Disease

Revista do Instituto de Medicina Tropical de Sao Paulo
MedicineInfectious Diseases
2013English

Selection of an Appropriate Thresholding Technique to Quantitate Fluorescence

Microscopy and Microanalysis
Instrumentation
2003English

ASCA: Genetic Marker, Predictor of Disease, or Marker of a Response to an Environmental Antigen?

Gut
Gastroenterology
2005English

A Clinical Biomarker Assay to Quantitate MIP-1 in Human Serum

Biomarkers and Applications
2017English

Formation of a Monoclonal Antibody Against Glycyrrhizin and Development of an ELISA.

Biological and Pharmaceutical Bulletin
MedicinePharmacologyPharmaceutical Science
1998English

Oscillatory Connectivity as a Diagnostic Marker of Dementia Due to Alzheimer’s Disease

Clinical Neurophysiology
Sensory SystemsNeurologyPhysiology
2019English

FLT3 as a Marker of Minimal Residual Disease: Time to Re-Think?

American Journal of Hematology
Hematology
2017English

Development of an Analytical Method to Determine Malondialdehyde as an Oxidative Marker in Cryopreserved Bovine Semen

Analytical Methods
EngineeringAnalytical ChemistryChemical Engineering
2015English

Methods to Quantitate Videocapsule Endoscopy Images in Celiac Disease

Bio-Medical Materials and Engineering
MedicineBiomaterialsBiomedical Engineering
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy